USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients

CPHI & PMEC China 2023 to see surge from pent up international ingredients demand

China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey

CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma

Aptar Digital Health and Healint collaborate for Central Nervous System

The partnership will capitalize on the combined capabilities of the two organizations

Kokilaben Hospital launches dedicated Hereditary Cancer Clinic

Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

PI Industries announces twin acquisitions into Pharma API & CDMO space

Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide

The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science

Venus Remedies secures marketing authorization from UK MHRA for Cisplatin

Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country

Siegfried breaks ground on new R&D center for drug substances in Switzerland

The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth